CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP) from its SEC filings: 2025 revenue $3.5 million (-91% vs the year before), net margin -16570%, free cash flow -$345.9 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $3.5 million |
| Revenue growth | -91% |
| Net income | -$581.6 million |
| Net margin | -16569.8% |
| Free cash flow | -$345.9 million |
| Diluted EPS | $-6.47 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +1041% |
| Cash | $291.3 million |
| Long-term debt | $586.2 million |
| Share count, 1 year | +6% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.